

SEND **QUEST DIAGNOSTICS NI**
 TO: **Attn: C/S Sample Reports only**
33608 ORTEGA HIGHWAY
SAN JUAN CAPISTRANO, CA 92675



Quest Diagnostics
 Quest Diagnostics Incorporated
 33608 Ortega Hwy., San Juan Capistrano, CA 92675
 CLIENT SERVICES - (800) 553-5445
 Director: Jon Nakamoto, M.D., Ph. D.

PATIENT NAME 16811, CellSearch(R) Circul			PATIENT ID NO. NOT GIVEN		DATE NOT GIVEN	TIME NOT GIVEN
ACCESSION NO. 47648232	AGE NG	SEX NG	SAMPLE ID NO. NOT GIVEN	OTHER ID NO. NG	COLLECTED 09/28/2017	RECEIVED 05:23
REMARKS			REFERRING PHYSICIAN NG		REPORTED 09/28/2017	05:24
					STATUS DUPLICATE	

TEST CellSearch(R), Colon **RESULT (* = OUT OF RANGE)** **UNITS** 1 **REFERENCE RANGE** CTC/7.5 mL Whole Blood

Interpretation/Comment:

A circulating tumor cell (CTC) count of 3 or more per 7.5 ml of blood at any time during the course of the disease has been reported to be associated with a poor prognosis and is predictive of shorter progression free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. The table lists median PFS and OS based CTC counts.

Number of CTC	PFS (months)	OS (months)
At all time <3	8.1	18.6
Baseline <3; At final draw >=3	4.3	7.1
Baseline >=3; At final draw <3	7.2	11.7
At all time points >=3	2.2	3.9

CellSearch(TM) results should be used in conjunction with all clinical information derived from diagnostic tests (i.e., imaging, laboratory tests), physical examination and complete medical history in accordance with appropriate patient management procedures. This prognostic study does not demonstrate that any current line of therapy is any more or less effective than any other or no therapy.

Reference:

- Veridex product insert, document LBL50058, Rev. 6, 2009-05.
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2008 Jul 1;26(19):3213-21.